Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Anti-CD19 CAR T cells||Anti-CD19 CAR T cells are T-cells that express a chimeric antigen receptor that targets the CD19 surface protein on B-lymphocytes, which results in anti-tumor activity in B-cell malignancies (PMID: 25999455, PMID: 26425336).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|NRAS G12D||B-lymphoblastic leukemia/lymphoma with BCR-ABL1||predicted - sensitive||Anti-CD19 CAR T cells||Case Reports/Case Series||Actionable||In a clinical case study, an investigational CD19-directed CAR T cells therapy resulted in rapid elimination of leukemic cells, including a subclone harboring NRAS G12D, in a patient with relapsed Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia, the NRAS G12D subclone remained undetectable at disease progression 6 weeks after treatment (PMID: 31905241).||31905241|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01853631||Phase I||Anti-CD19 CAR T cells Cyclophosphamide + Fludarabine||Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN)||Recruiting|
|NCT03938987||Phase Ib/II||Cyclophosphamide + Fludarabine Anti-CD19 CAR T cells||Anti-CD19, Dual Co-stimulatory (4-1BB, CD3zeta) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002)||Not yet recruiting|
|NCT03016377||Phase Ib/II||Anti-CD19 CAR T cells Cyclophosphamide + Fludarabine||Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL||Recruiting|
|NCT01087294||Phase I||Anti-CD19 CAR T cells||Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation||Recruiting|